Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial

Conclusions These data suggest that in patients with ANCA-associated vasculitis receiving rituximab, efficacy of treatment with avacopan compared with a prednisone taper was similar at week 26 and greater at week 52, with a favourable safety profile. In addition, avacopan was associated with improved renal outcomes and lower glucocorticoid toxicity. These results demonstrate the efficacy and safety of avacopan in patients receiving background induction therapy with rituximab. Trial registration number NCT02994927.

http://ard.bmj.com/cgi/content/short/83/2/223?rss=1

Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Geetha, D., Dua, A., Yue, H., Springer, J., Salvarani, C., Jayne, D., Merkel, P., ADVOCATE Study Group, Au Peh, Chakera, Cooper, Kurtkoti, Langguth, Levidiotis, Luxton, Mount, Mudge, Noble, Phoon, Ritchie, Ryan, Suranyi, Rosenkranz, Kronbichler, Demoulin, Tags: Open access, ARD, Vasculitis Source Type: research